DR-0202
Phase 1Small molecule
DR-0202 is one of 40 small molecule programs targeting Relapsed or Refractory. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Relapsed or Refractory
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Cytosar
TevaPhase 2
Fludara
SanofiPhase 2
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 2
Oncovin
Eli LillyPhase 2
Fludara
SanofiPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Libtayo
RegeneronPhase 2
Tepadina
Jazz PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DR-0202. EMBL-EBI & Wellcome Sanger Institute.
- [4]